Skip to main content
Explore URMC
menu

Safety and Efficacy of KTE-X19 in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia (ZUMA-8)

Research Question:
What is the safety and efficacy of KTE-X19 in adults with relapsed/refractory chronic lymphocytic leukemia (r/r CLL)?

Basic Study Information

Purpose:
Participants will receive conditioning chemotherapy (fludarabine and cyclophosphamide), followed by the investigational treatment, KTE-X19. KTE-X19 is a CAR-T Cell Therapy (infusion).

Location: University of Rochester Medical Center
Study Reference #: IBMT18146

Lead Researcher (Principal Investigator)

Lead Researcher: Patrick Reagan

Study Contact Information

Study Coordinator: Andrew Bui
Phone: (585) 276-4405
Email: Andrew_Bui@URMC.Rochester.edu

Additional Study Details

Return to Search